Volume 11, Issue 1 (2025)
CJP 2025, 11(1): e13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Padar C, Rajan A, Oommen R. Role of Probiotics in Preterm and Low Birth Weight Infants: A Randomised Controlled Trial. CJP 2025; 11 (1)
URL: http://caspianjp.ir/article-1-264-en.html
URL: http://caspianjp.ir/article-1-264-en.html
A.J. Institute of Medical Sciences, Mangaluru, India , ar_aswathy@yahoo.com
Abstract: (14 Views)
Background and Objective: Bifidobacteria are part of the natural intestinal flora of neonates, but their role as a single probiotic in reducing sepsis and necrotizing enterocolitis (NEC) is still under investigation. The aim of this study was to determine the effect of Bifidobacterium breve M-16 V on morbidity and mortality in preterm and low-birth-weight neonates.
Methods: A randomized controlled trial was conducted >18 months on infants with gestational age between 28 and 36 weeks and 6 days or birth weight between 1000 and 2499 grams in whom enteral feeding was initiated within the first week. They were randomly divided to receive the probiotic or placebo. The primary endpoint was the incidence of neonatal sepsis or mortality. Secondary endpoints included the occurrence of NEC, jaundice, length of hospital stay, and weight gain.
Findings: Among the 63 infants analyzed as the test group and 61 as the control group, no statistically significant differences were found between the groups in the incidence of neonatal sepsis (11.1% versus 14.7%; RR 0.75; [95% CI 0.3 to 1.8], p =0.54), NEC, jaundice, or length of hospital stay with probiotic supplementation. The mean weight gain was 982 ± 336 grams in the probiotic group, which was significantly higher than 848 ± 340 grams in the control group (p=0.02).
Conclusion: Supplementation with Bifidobacterium breve M-16 V indicated no significant effect on most parameters studied. However, infants supplemented with Bifidobacterium breve M-16 V showed a significantly higher weight gain after 6 weeks.
Methods: A randomized controlled trial was conducted >18 months on infants with gestational age between 28 and 36 weeks and 6 days or birth weight between 1000 and 2499 grams in whom enteral feeding was initiated within the first week. They were randomly divided to receive the probiotic or placebo. The primary endpoint was the incidence of neonatal sepsis or mortality. Secondary endpoints included the occurrence of NEC, jaundice, length of hospital stay, and weight gain.
Findings: Among the 63 infants analyzed as the test group and 61 as the control group, no statistically significant differences were found between the groups in the incidence of neonatal sepsis (11.1% versus 14.7%; RR 0.75; [95% CI 0.3 to 1.8], p =0.54), NEC, jaundice, or length of hospital stay with probiotic supplementation. The mean weight gain was 982 ± 336 grams in the probiotic group, which was significantly higher than 848 ± 340 grams in the control group (p=0.02).
Conclusion: Supplementation with Bifidobacterium breve M-16 V indicated no significant effect on most parameters studied. However, infants supplemented with Bifidobacterium breve M-16 V showed a significantly higher weight gain after 6 weeks.
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
